Erratum: CD95L cell surface cleavage triggers a prometastatic signaling pathway in triple-negative breast cancer (Cancer Research (2013) 73 (6711–6721) DOI: 10.1158/0008-5472.CAN-13-1794);CD95L cell surface cleavage triggers a prometastatic signaling pathway in triple-negative breast cancer

Cancer Research

Volumn 73, Issue 22, 2013, Pages 6711-6721

  Malleter, Marine ^a,b   Tauzin, Sébastien ^a,b   Bessede, Alban ^d   Castellano, Rémy ^e   Goubard, Armelle ^e   Godey, Florence ^a,c   Levêque, Jean ^a,b   Jézéquel, Pascal ^f   Campion, Loic ^f   Campone, Mario ^f   Ducret, Thomas ^g,h   MacGrogan, Gaëtan ⁱ   Debure, Laure ^a,b   Collette, Yves ^e   Vacher, Pierre ^g,i   Legembre, Patrick ^a,b  

^a UNIVERSITÉ DE RENNES 1   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

^c CENTRE EUGÈNE MARQUIS   (France)

^d ImmuSmol   (France)

^e AIX MARSEILLE UNIVERSITY   (France)

^f ICO René Gauducheau ^*  (France)

^g UNIVERSITÉ DE BORDEAUX   (France)

^h CENTRE DE RECHERCHE CARDIO THORACIQUE DE BORDEAUX   (France)

ⁱ INSTITUT BERGONIÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; CALCIUM RELEASE ACTIVATED CALCIUM CHANNEL 1; EPIDERMAL GROWTH FACTOR RECEPTOR; FAS LIGAND; METALLOPROTEINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 3; OXIDOREDUCTASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE YES; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOGENESIS; CANCER CELL; CANCER CELL CULTURE; CANCER TISSUE; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER;

EID: 84888376754     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-19-3636     Document Type: Erratum

References (34)

1. Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012;379:432-44.
2. Tauzin S, Debure L, Moreau JF, Legembre P. CD95-mediated cell signaling in cancer: mutations and posttranslational modulations. Cell Mol Life Sci 2012;69:1261-77.
3. Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, Fontana A, et al. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 1998;187:1205-13.
4. Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med 1997;186:2045-50.
5. O'Reilly LA, Tai L, Lee L, Kruse EA, Grabow S, Fairlie WD, et al. Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature 2009;461:659-63.
6. Tauzin S, Chaigne-Delalande B, Selva E, Khadra N, Daburon S, Contin-Bordes C, et al. The naturally processed CD95L elicits a c-yes/calcium/PI3K-driven cell migration pathway. PLoS Biol 2011;9:e1001090.
7. Chen L, Park SM, Tumanov AV, Hau A, Sawada K, Feig C, et al. CD95 promotes tumour growth. Nature 2010;465:492-6.
8. Bivona TG, Hieronymus H, Parker J, Chang K, Taron M, Rosell R, et al. FAS and NF-kappaB signalling modulate dependence of lung cancers on mutant EGFR. Nature 2011;471:523-6.
9. Kischkel FC, Hellbardt S, Behrmann I, Germer M, Pawlita M, Krammer PH, et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. Embo J 1995;14:5579-88.
10. Kleber S, Sancho-Martinez I, Wiestler B, Beisel A, Gieffers C, Hill O, et al. Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 2008;13:235-48.
11. Khadra N, Bresson-Bepoldin L, Penna A, Chaigne-Delalande B, Segui B, Levade T, et al. CD95 triggers Orai1-mediated localized Ca2+ entry, regulates recruitment of protein kinase C (PKC) beta2, and prevents death-inducing signaling complex formation. Proc Natl Acad Sci U S A 2011;108:19072-7.
12. Reimer T, Herrnring C, Koczan D, Richter D, Gerber B, Kabelitz D, et al. FasL:Fas ratio - a prognostic factor in breast carcinomas. Cancer Res 2000;60:822-8.
13. Qiao M, Sheng S, Pardee AB. Metastasis and AKT activation. Cell Cycle 2008;7:2991-6.
14. Vanhaesebroeck B, Stephens L, Hawkins P. PI3K signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol 2012;13:195-203.
15. Evans JH, Falke JJ. Ca2+ influx is an essential component of the positive-feedback loop that maintains leading-edge structure and activity in macrophages. Proc Natl Acad Sci U S A 2007;104:16176-81.
16. Oh-hora M, Rao A. Calcium signaling in lymphocytes. Curr Opin Immunol 2008;20:250-8.
17. Cahalan MD. STIMulating store-operated Ca(2+) entry. Nat Cell Biol 2009;11:669-77.
18. Qian D, Weiss A. T cell antigen receptor signal transduction. Curr Opin Cell Biol 1997;9:205-12.
19. Yoo SK, Starnes TW, Deng Q, Huttenlocher A. Lyn is a redox sensor that mediates leukocyte wound attraction in vivo. Nature 2011;480:109-12.
20. Al Ghouleh I, Khoo NK, Knaus UG, Griendling KK, Touyz RM, Thannickal VJ, et al. Oxidases and peroxidases in cardiovascular and lung disease: new concepts in reactive oxygen species signaling. Free Radic Biol Med 2011;51:1271-88.
21. Dinkel H, Michael S, Weatheritt RJ, Davey NE, Van Roey K, Altenberg B, et al. ELM - the database of eukaryotic linear motifs. Nucleic Acids Res 2012;40:D242-51.
22. Biscardi JS, Maa MC, Tice DA, Cox ME, Leu TH, Parsons SJ. c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J Biol Chem 1999;274:8335-43.
23. Biscardi JS, Ishizawar RC, Silva CM, Parsons SJ. Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Res 2000;2:203-10.
24. Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol 2010;7:683-92.
25. Nie F, Yang J, Wen S, An YL, Ding J, Ju SH, et al. Involvement of epidermal growth factor receptor overexpression in the promotion of breast cancer brain metastasis. Cancer 2012;118:5198-209.
26. Mano M, Humblet Y. Drug insight: panitumumab, a human EGFR-targeted monoclonal antibody with promising clinical activity in colorectal cancer. Nat Clin Pract Oncol 2008;5:415-25.
27. Filosto S, Khan EM, Tognon E, Becker C, Ashfaq M, Ravid T, et al. EGF receptor exposed to oxidative stress acquires abnormal phosphorylation and aberrant activated conformation that impairs canonical dimerization. PLoS ONE 2011;6:e23240.
28. Luttrell LM, Della Rocca GJ, van Biesen T, Luttrell DK, Lefkowitz RJ. Gbetagamma subunits mediate Src-dependent phosphorylation of the epidermal growth factor receptor. A scaffold for G protein-coupled receptor-mediated Ras activation. J Biol Chem 1997;272:4637-44.
29. Zou C, Ma J, Wang X, Guo L, Zhu Z, Stoops J, et al. Lack of Fas antagonism by Met in human fatty liver disease. Nat Med 2007;13:1078-85.
30. Edmond V, Ghali B, Penna A, Taupin JL, Daburon S, Moreau JF, et al. Precise mapping of the CD95 pre-ligand assembly domain. PLoS ONE 2012;7:e46236.
31. Wang X, DeFrances MC, Dai Y, Pediaditakis P, Johnson C, Bell A, et al. A mechanism of cell survival: sequestration of Fas by the HGF receptor Met. Mol Cell 2002;9:411-21.
32. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-92.
33. Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 2005;102:7665-70.
34. Tuettenberg J, Seiz M, Debatin KM, Hollburg W, von Staden M, Thiemann M, et al. Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patients. Int Immunopharmacol 2012;13:93-100.